menu
    • menu
    [{"orgOrder":0,"company":"Strand Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"$320.0 million","upfrontCash":"Undisclosed","newsHeadline":"Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"mRNA-based therapeutics","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Strand Therapeutics","amount2":0.32000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.32000000000000001,"dosageForm":"Intratumoral Injection","sponsorNew":"Strand Therapeutics \/ BeiGene","highestDevelopmentStatusID":"4","companyTruncated":"Strand Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"Strand Therapeutics","sponsor":"Redmile Group","pharmaFlowCategory":"D","amount":"$52.0 million","upfrontCash":"Undisclosed","newsHeadline":"Strand Therapeutics Raises $52M in Oversubscribed Series A Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series A Financing","leadProduct":"mRNA-based Therapeutics","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Strand Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Strand Therapeutics \/ Redmile Group","highestDevelopmentStatusID":"4","companyTruncated":"Strand Therapeutics \/ Redmile Group"},{"orgOrder":0,"company":"Strand Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"Strand Therapeutics Awarded Two Phase I NIH SBIR Grants to Advance Programmable for Melanoma and Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Funding","leadProduct":"mRNA-based Therapeutics","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Strand Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Strand Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Strand Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Strand Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"Strand Therapeutics Awarded Phase I NIH SBIR Contract to Develop mRNA-based CAR-T Immunotherapy for Non-Hodgkin\u2019s Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Funding","leadProduct":"mRNA-based CAR-T Immunotherapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Strand Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Strand Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Strand Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Strand Therapeutics","sponsor":"FPV","pharmaFlowCategory":"D","amount":"$97.0 million","upfrontCash":"Undisclosed","newsHeadline":"Strand Therapeutics Announces Series A1 Bringing Total Round to US$97 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Series A Financing","leadProduct":"mRNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Strand Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Strand Therapeutics \/ FPV","highestDevelopmentStatusID":"4","companyTruncated":"Strand Therapeutics \/ FPV"},{"orgOrder":0,"company":"Strand Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strand doses first patient with mRNA Therapy STX-001 in Phase 1 solid tumor trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Strand Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Strand Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Strand Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Strand Therapeutics

    Menu

    Strand Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Strand Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Strand Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STX-001,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Strand doses first patient with mRNA Therapy STX-001 in Phase 1 solid tumor trial

                            Details : STX-001 is a novel programmable self-replicating mRNA encapsulated in lipid nanoparticles (LNPs), being evaluated for THE treatment of advanced solid tumors.

                            Brand Name : STX-001

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 30, 2024

                            Lead Product(s) : STX-001,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Strand Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Strand Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : FPV

                            Deal Size : $97.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Strand Therapeutics Announces Series A1 Bringing Total Round to US$97 Million

                            Details : The funding will be used to advance Strand’s first drug candidate, a programmable mRNA therapy for solid tumor immuno-oncology into Phase 1 clinical trials next year.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 28, 2022

                            Lead Product(s) : mRNA-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : FPV

                            Deal Size : $97.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Strand Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Strand Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-based CAR-T Immunotherapy

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : National Institutes of Health

                            Deal Size : $0.4 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Strand Therapeutics Awarded Phase I NIH SBIR Contract to Develop mRNA-based CAR-T Immunotherapy for Non-Hodgki...

                            Details : Strand will use the funds from the contract to develop an in situ, off-the-shelf cell therapy based on the company’s proprietary self-replication, programmable mRNA platform to illicit a targeted CD19 CAR-T response.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 09, 2021

                            Lead Product(s) : mRNA-based CAR-T Immunotherapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : National Institutes of Health

                            Deal Size : $0.4 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Strand Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Strand Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-based Therapeutics

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $0.8 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Strand Therapeutics Awarded Two Phase I NIH SBIR Grants to Advance Programmable for Melanoma and Breast Cancer

                            Details : Strand Therapeutics awarded two Phase I Small Business Innovation Research (SBIR) grants from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to develop mRNA-based therapeutics for melanoma and triple negative breast cancer...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 04, 2021

                            Lead Product(s) : mRNA-based Therapeutics

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $0.8 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Strand Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Strand Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-based Therapeutics

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Redmile Group

                            Deal Size : $52.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Strand Therapeutics Raises $52M in Oversubscribed Series A Round

                            Details : Financing oversubscribed; proceeds from the round will be used to expand Strand’s growing mRNA platforms into multiple immuno-oncology and disease settings, and advance lead drug into Phase 1 clinical trials.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 23, 2021

                            Lead Product(s) : mRNA-based Therapeutics

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Redmile Group

                            Deal Size : $52.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Strand Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Strand Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-based therapeutics

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : BeiGene

                            Deal Size : $320.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics

                            Details : BeiGene gets option to license to develop and commercialize in Asia, Australia, and New Zealand up to two immuno-oncology programs using Strand’s intratumoral or systemic delivery mechanism, to deliver a tumor microenvironment-modifying mRNA directly t...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 11, 2021

                            Lead Product(s) : mRNA-based therapeutics

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : BeiGene

                            Deal Size : $320.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth